Aptose Biosciences Inc.

Aptose reported no revenue in Q1 2024. Net loss was approximately $9.6 million, or $0.73 per share, versus a $13.7 million loss, or $2.22 per share, in Q1 2023. Research and development expense was approximately $6.4 million, down from $8.8 million a year ago; tuspetinib program costs were $3.9 million versus $4.8 million; luxeptinib program costs were $208,000 versus $1.3 million; and G&A expense was $3.3 million versus $5.3 million. The company ended the quarter with approximately $9.3 million in cash, cash equivalents, and investments, and management said that cash plus the ATM should fund planned operations, including R&D, through August 2024. No revenue guidance was provided; instead, management guided to several clinical milestones: EHA in June 2024, first dosing in the triplet study in summer 2024, ASH 2024 triplet response/MRD/safety data, and a fuller data readout in summer 2025.

Dr. Rice framed the quarter as a strategic inflection point, saying Aptose is accelerating tuspetinib into a frontline AML triplet because the biggest unmet need is a better initial therapy for newly diagnosed patients. He repeatedly emphasized that tuspetinib’s appeal is its combination of broad activity, including in wild-type AML, and a safety profile that may allow standard venetoclax/HMA dosing to be preserved. His tone was confident and promotional about the scientific rationale, while still anchoring the plan in upcoming clinical readouts rather than commercial claims.

Fletcher Payne said the company continued disciplined cost control in Q1, reducing spending and prioritizing clinical programs. He cited approximately $9.3 million in cash, cash equivalents, and investments at quarter-end, with $11.8 million of January financing proceeds offset by $11.8 million used in operations. He also noted no revenue, a net loss of approximately $9.6 million, R&D of approximately $6.4 million, and G&A of $3.3 million. On capital and compliance, he highlighted 16,309,393 shares outstanding as of May 14, 2024, said cash plus the ATM should fund operations through August 2024, and discussed NASDAQ compliance issues including the earlier 19.99% warrant matter and a separate stockholders’ equity deficiency notice.

The main analyst question focused on how much the frontline triplet trial design reflected prior FDA feedback and what benchmark would define success. Management said the design largely came from discussions with experts, including lead PI Dr. Naval Daver, and the VEN-ASA label, not from back-and-forth with FDA. For success, management pointed to response rates above the roughly two-thirds rate seen with VEN-HMA, saying something closer to 75% would be encouraging, while also emphasizing that overall survival and preserved standard-of-care dosing would be the more important longer-term measures.